Fig. 2: αPD-L2 efficacy against melanoma in aged mice requires host IFNγ and IL-17. | Nature Communications

Fig. 2: αPD-L2 efficacy against melanoma in aged mice requires host IFNγ and IL-17.

From: Anti-PD-L2 immunotherapy is efficacious against melanoma in aged hosts through IL-17 and IFNγ signalling

Fig. 2: αPD-L2 efficacy against melanoma in aged mice requires host IFNγ and IL-17.

a Overall and individual tumour growth plots and b survival of aged IFNγKO mice bearing B16 melanomas treated with isotype (200 µg/mouse) or αPD-L2 (200 µg/mouse) (isotype n = 4 mice, αPD-L2 n = 5 mice). c Tumour growth curve of IL-17KO aged mice harboring B16 melanomas treated with αPD-L2 or isotype control as above (isotype n = 5 mice, αPD-L2 n = 4 mice). d Tumour growth curve of wild type aged mice harboring B16 melanomas treated with αPD-L2 or isotype control ± αIL-17 (100 µg/mouse) administered intraperitoneally starting on day 2, then twice weekly until day 19 (αPD-L2+isotype n = 5 mice, αPD-L2 + αIL-17 n = 4 mice). e Tumour growth curve of IL-17KO aged mice harboring NCH1 melanomas treated with αPD-L2 or isotype control as above (isotype n = 5 mice, αPD-L2 n = 5 mice). Standard error of mean indicated; p-values by (b) log-rank test for Kaplan-Meier survival curve, or (a, c–e) two-way ANOVA.

Back to article page